Search

P357 Long-term outcomes of biologic therapy in Crohn’s disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU

Rodríguez-Lago, I.(1);Fernández-Clotet, A.(2,3);Mesonero, F.(4);García-Alonso, F.J.(5);Casanova, M.J.(6);Fernández-de la Varga, M.(7);Cañete, F.(8);de Castro, L.(9);Gutiérrez, A.(10);Sicilia, B.(11);Cano, V.(12);Merino, O.(13);Riestra, S.(14);González-Partida, I.(15);Surís, G.(16);Torrealba, L.(17);Ferreiro-Iglesias, R.(18);Castro, B.(19);Márquez, L.(20);Sobrino, A.(21);Elorza, A.(1);Calvet, X.(22);Varela, P.(23);Betoré, E.(24);Bujanda, L.(25);Lario, L.(26);Manceñido, N.(27);García-Sepulcre, M.(28);Iglesias, E.(29);Rodríguez, C.(30);Piqueras, M.(31);Ferrer Rosique, J.Á.(32);Lucendo, A.(33);Benítez, O.(34);García, M.(35);Olivares, D.(36);González-Muñoza, C.(37);Cabriada, J.L.(1);Domènech, E.(8);Barreiro-de Acosta, M.(18);

(1)Hospital de Galdakao, Gastroenterology, Galdakao, Spain;(2)Hospital Clinic, Gastroenterology, Barcelona, Spain;(3)Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology, Madrid, Spain;(4)Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain;(5)Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Spain;(6)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Universidad Autónoma de Madrid UAM, Gastroenterology, Madrid, Spain;(7)Hospital Universitari i Politecnic la Fe, Gastroenterology, Valencia, Spain;(8)Hospital Universitari German Trias i Pujol, Gastroenterology, Badalona, Spain;(9)Hospital Álvaro Cunqueiro, Gastroenterology, Vigo, Spain;(10)Hospital General Universitario de Alicante, Gastroenterology, Alicante, Spain;(11)Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain;(12)Hospital Universitario de León, Gastroenterology, León, Spain;(13)Hospital Universitario de Cruces, Hospital Universitario de Cruces, Barakaldo, Spain;(14)Hospital Universitario Central de Asturias, Gastroenterology, Oviedo, Spain;(15)Hospital Universitario Puerta de Hierro, Gastroenterology, Madrid, Spain;(16)Hospital Universitari de Bellvitge, Gastroenterology, Barcelona, Spain;(17)Hospital Universitari Dr Josep Trueta, Gastroenterology, Girona, Spain;(18)Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology, Santiago de Compostela, Spain;(19)Hospital Universitario Marqués de Valdecilla, Gastroenterology, Santander, Spain;(20)Hospital de Mar, Gastroenterology, Barcelona, Spain;(21)Hospital General Universitario de Ciudad Real, Gastroenterology, Ciudad Real, Spain;(22)Corporació Sanitària Universitària Parc Taulí, Gastroenterology, Sabadell, Spain;(23)Hospital de Cabueñes, Gastroenterology, Gijón, Spain;(24)Hospital Universitario Miguel Servet, Hospital Universitario Miguel Servet, Zaragoza, Spain;(25)Hospital Universitario Donostia, Gastroenterology, Donostia, Spain;(26)Hospital Clínico Universitario Lozano Blesa, Gastroenterology, Zaragoza, Spain;(27)Hospital Universitario Infanta Sofía, Gastroenterology, Madrid, Spain;(28)Hospital General Universitario de Elche, Gastroenterology, Elche, Spain;(29)Hospital Universitario Reina Sofía- IMIBIC, Gastroenterology, Córdoba, Spain;(30)Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain;(31)Consorci Sanitari de Terrassa, Gastroenterology, Terrassa, Spain;(32)Hospital Universitario Fundación Alcorcón, Gastroenterology, Alcorcón, Spain;(33)Hospital General de Tomelloso, Gastroenterology, Tomelloso, Spain;(34)Hospital Universitari Mútua Terrassa, Gastroenterology, Terrassa, Spain;(35)Hospital General San Jorge, Hospital General San Jorge, Huesca, Spain;(36)Hospital Clínico San Carlos, Gastroenterology, Madrid, Spain;(37)Hospital Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain; on behalf of the BIOSCOPE study group from the ENEIDA registry

Background

The prevalence of penetrating disease in Crohn’s disease (CD) increases progressively over time, and evidence on the medical treatment of this complication is limited. The aim of this study was to evaluate the efficacy of biologic agents in CD complicated with internal fistulising disease.

Methods

A retrospective analysis of all adult patients from the ENEIDA registry (>68,000 patients) with CD who received at least one biologic agent -anti-TNF, ustekinumab or vedolizumab- for penetrating disease was performed. Exclusion criteria comprised treatment for perianal disease, enterocutaneous, anastomotic or periostomal fistula tracts. The main outcomes were fistula-related surgery and fistula closure on cross-sectional imaging. Preestablished secondary outcomes included the rate of abdominal abscess, the need for percutaneous drainage, the changes in the number of fistula tracts, fistula closure rates, and the safety profile.The baseline characteristics were analyzed by means of descriptive statistics and were compared by non-parametric tests. Predictive factors associated with surgery and fistula closure were evaluated by a multivariable logistic regression and survival analyses.

Results

A total of 710 patients (median age 38 years [IQR, 28-48], 59% male, 55% L3) receiving 791 biologic treatments were included at 53 sites (701 anti-TNF, 71 ustekinumab, and 19 vedolizumab). Patients had a median of 1 (range 1-5) fistula tracts, 49% of them entero-enteric followed by entero-colic (28%). After a median follow-up of 59 months (IQR, 27-105), 244 patients (31%) required surgery due to internal fistulising complications after 8.5 months (IQR, 3-24). Patients with ileocolonic disease (OR 1.99 [1.22-3.23]), entero-urinary fistulas (OR 2.35 [1.17-4.73]), or with a stricture distal to the fistula (OR 2.1 [1.31-3.36]) showed a higher risk of surgery, with no differences between biologic drugs (Figure 1). Combination therapy reduced the risk of surgery (HR 0.58 [0.37-0.90]). Fistula closure was observed in 24% of patients after a median of 15 months (IQR, 7.5-27). Patients with a lower number of fistula tracts showed a higher probability of closure  (OR 1.72 [1.09-2.7]).

Conclusion

A high proportion of patients with internal fistulizing CD benefit from biologic treatment after a median of 5 years. During this follow-up, around two thirds of patients are free of surgery and one in every four patients achieves fistula closure.

Portal